nodes	percent_of_prediction	percent_of_DWPC	metapath
Floxuridine—TYMS—Methotrexate—bone cancer	0.686	1	CbGbCtD
Floxuridine—TYMP—Pyrimidine catabolism—NT5C3A—bone cancer	0.0496	0.227	CbGpPWpGaD
Floxuridine—TYMP—Pyrimidine metabolism—NT5C3A—bone cancer	0.0285	0.13	CbGpPWpGaD
Floxuridine—TYMS—Pyrimidine metabolism—NT5C3A—bone cancer	0.0146	0.0667	CbGpPWpGaD
Floxuridine—TYMP—Nucleotide metabolism—NT5C3A—bone cancer	0.0111	0.0508	CbGpPWpGaD
Floxuridine—TYMP—Fluoropyrimidine Activity—DHFR—bone cancer	0.00898	0.0411	CbGpPWpGaD
Floxuridine—TYMS—G1/S-Specific Transcription—DHFR—bone cancer	0.00781	0.0357	CbGpPWpGaD
Floxuridine—Nail changes—Methotrexate—bone cancer	0.00611	0.0642	CcSEcCtD
Floxuridine—TYMS—Nucleotide metabolism—NT5C3A—bone cancer	0.00568	0.026	CbGpPWpGaD
Floxuridine—TYMS—One Carbon Metabolism—DHFR—bone cancer	0.00524	0.024	CbGpPWpGaD
Floxuridine—TYMP—Bladder Cancer—CDK4—bone cancer	0.00496	0.0227	CbGpPWpGaD
Floxuridine—TYMS—Trans-sulfuration and one carbon metabolism—DHFR—bone cancer	0.00471	0.0215	CbGpPWpGaD
Floxuridine—TYMS—E2F mediated regulation of DNA replication—DHFR—bone cancer	0.00459	0.021	CbGpPWpGaD
Floxuridine—TYMS—Fluoropyrimidine Activity—DHFR—bone cancer	0.00459	0.021	CbGpPWpGaD
Floxuridine—TYMP—Bladder Cancer—BRAF—bone cancer	0.00439	0.0201	CbGpPWpGaD
Floxuridine—TYMP—Bladder Cancer—RB1—bone cancer	0.00431	0.0197	CbGpPWpGaD
Floxuridine—TYMP—Bladder Cancer—MDM2—bone cancer	0.00367	0.0168	CbGpPWpGaD
Floxuridine—Arterial thrombosis—Methotrexate—bone cancer	0.00329	0.0346	CcSEcCtD
Floxuridine—TYMS—Circadian rythm related genes—TNFRSF11A—bone cancer	0.00299	0.0137	CbGpPWpGaD
Floxuridine—Enteritis—Methotrexate—bone cancer	0.0026	0.0273	CcSEcCtD
Floxuridine—TYMP—Bladder Cancer—EGFR—bone cancer	0.00251	0.0115	CbGpPWpGaD
Floxuridine—TYMS—E2F transcription factor network—DHFR—bone cancer	0.00243	0.0111	CbGpPWpGaD
Floxuridine—TYMS—Retinoblastoma (RB) in Cancer—DHFR—bone cancer	0.00211	0.00967	CbGpPWpGaD
Floxuridine—TYMP—Bladder Cancer—TP53—bone cancer	0.00211	0.00964	CbGpPWpGaD
Floxuridine—TYMS—E2F mediated regulation of DNA replication—RB1—bone cancer	0.0021	0.00959	CbGpPWpGaD
Floxuridine—Abscess—Cisplatin—bone cancer	0.00204	0.0214	CcSEcCtD
Floxuridine—TYMP—Fluoropyrimidine Activity—TP53—bone cancer	0.00201	0.00917	CbGpPWpGaD
Floxuridine—Infection—Carboplatin—bone cancer	0.00195	0.0205	CcSEcCtD
Floxuridine—TYMS—G1/S Transition—DHFR—bone cancer	0.00177	0.00807	CbGpPWpGaD
Floxuridine—Body temperature increased—Carboplatin—bone cancer	0.00155	0.0163	CcSEcCtD
Floxuridine—TYMS—Mitotic G1-G1/S phases—DHFR—bone cancer	0.00149	0.0068	CbGpPWpGaD
Floxuridine—Lacrimation—Epirubicin—bone cancer	0.00141	0.0148	CcSEcCtD
Floxuridine—Embolism—Methotrexate—bone cancer	0.00138	0.0145	CcSEcCtD
Floxuridine—Nail disorder—Methotrexate—bone cancer	0.00137	0.0144	CcSEcCtD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.00135	0.0062	CbGpPWpGaD
Floxuridine—TYMS—E2F transcription factor network—PLAU—bone cancer	0.00135	0.00618	CbGpPWpGaD
Floxuridine—Lacrimation—Doxorubicin—bone cancer	0.00131	0.0137	CcSEcCtD
Floxuridine—Embolism—Epirubicin—bone cancer	0.00129	0.0136	CcSEcCtD
Floxuridine—TYMS—Cell Cycle, Mitotic—ZW10—bone cancer	0.00128	0.00586	CbGpPWpGaD
Floxuridine—Nail disorder—Epirubicin—bone cancer	0.00128	0.0134	CcSEcCtD
Floxuridine—TYMP—Metabolism—NDUFA12—bone cancer	0.00122	0.00557	CbGpPWpGaD
Floxuridine—Embolism—Doxorubicin—bone cancer	0.0012	0.0126	CcSEcCtD
Floxuridine—Nail disorder—Doxorubicin—bone cancer	0.00118	0.0124	CcSEcCtD
Floxuridine—Nystagmus—Epirubicin—bone cancer	0.00116	0.0122	CcSEcCtD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.00115	0.00527	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle—ZW10—bone cancer	0.00115	0.00524	CbGpPWpGaD
Floxuridine—Abscess—Methotrexate—bone cancer	0.00112	0.0118	CcSEcCtD
Floxuridine—TYMS—E2F transcription factor network—RB1—bone cancer	0.00111	0.00508	CbGpPWpGaD
Floxuridine—TYMS—Retinoblastoma (RB) in Cancer—CDK4—bone cancer	0.00111	0.00508	CbGpPWpGaD
Floxuridine—Nystagmus—Doxorubicin—bone cancer	0.00108	0.0113	CcSEcCtD
Floxuridine—Cramp muscle—Cisplatin—bone cancer	0.00106	0.0111	CcSEcCtD
Floxuridine—Abscess—Epirubicin—bone cancer	0.00105	0.011	CcSEcCtD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.00105	0.0048	CbGpPWpGaD
Floxuridine—TYMS—Fluoropyrimidine Activity—TP53—bone cancer	0.00103	0.00469	CbGpPWpGaD
Floxuridine—TYMS—Circadian rythm related genes—GNA11—bone cancer	0.00101	0.00463	CbGpPWpGaD
Floxuridine—TYMP—Metabolism—NT5C3A—bone cancer	0.00101	0.00461	CbGpPWpGaD
Floxuridine—TYMS—Circadian rythm related genes—EZH2—bone cancer	0.00101	0.0046	CbGpPWpGaD
Floxuridine—Abscess—Doxorubicin—bone cancer	0.000971	0.0102	CcSEcCtD
Floxuridine—TYMS—Cell Cycle, Mitotic—TUBB4B—bone cancer	0.000971	0.00444	CbGpPWpGaD
Floxuridine—TYMS—Retinoblastoma (RB) in Cancer—RB1—bone cancer	0.000966	0.00442	CbGpPWpGaD
Floxuridine—Pancytopenia—Cisplatin—bone cancer	0.000963	0.0101	CcSEcCtD
Floxuridine—Glossitis—Methotrexate—bone cancer	0.000963	0.0101	CcSEcCtD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000955	0.00437	CbGpPWpGaD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000942	0.00431	CbGpPWpGaD
Floxuridine—Glossitis—Epirubicin—bone cancer	0.000901	0.00945	CcSEcCtD
Floxuridine—Lacrimation increased—Epirubicin—bone cancer	0.000901	0.00945	CcSEcCtD
Floxuridine—Stomatitis—Cisplatin—bone cancer	0.000881	0.00925	CcSEcCtD
Floxuridine—TYMS—Cell Cycle, Mitotic—RFC1—bone cancer	0.00088	0.00403	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle—TUBB4B—bone cancer	0.000868	0.00397	CbGpPWpGaD
Floxuridine—Glossitis—Doxorubicin—bone cancer	0.000833	0.00875	CcSEcCtD
Floxuridine—Lacrimation increased—Doxorubicin—bone cancer	0.000833	0.00875	CcSEcCtD
Floxuridine—TYMS—Retinoblastoma (RB) in Cancer—MDM2—bone cancer	0.000823	0.00377	CbGpPWpGaD
Floxuridine—TYMS—G1/S Transition—RB1—bone cancer	0.000806	0.00369	CbGpPWpGaD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000798	0.00365	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle—RFC1—bone cancer	0.000787	0.0036	CbGpPWpGaD
Floxuridine—TYMS—Mitotic G1-G1/S phases—CDK4—bone cancer	0.000781	0.00357	CbGpPWpGaD
Floxuridine—Rash maculo-papular—Epirubicin—bone cancer	0.000755	0.00792	CcSEcCtD
Floxuridine—Thrombophlebitis—Methotrexate—bone cancer	0.000744	0.00781	CcSEcCtD
Floxuridine—Photosensitivity—Methotrexate—bone cancer	0.000733	0.0077	CcSEcCtD
Floxuridine—Alopecia—Cisplatin—bone cancer	0.000717	0.00753	CcSEcCtD
Floxuridine—Erythema—Cisplatin—bone cancer	0.000707	0.00742	CcSEcCtD
Floxuridine—Rash maculo-papular—Doxorubicin—bone cancer	0.000698	0.00733	CcSEcCtD
Floxuridine—Thrombophlebitis—Epirubicin—bone cancer	0.000696	0.00731	CcSEcCtD
Floxuridine—Photosensitivity—Epirubicin—bone cancer	0.000686	0.0072	CcSEcCtD
Floxuridine—TYMS—Mitotic G1-G1/S phases—RB1—bone cancer	0.000679	0.00311	CbGpPWpGaD
Floxuridine—Muscle spasms—Cisplatin—bone cancer	0.000679	0.00713	CcSEcCtD
Floxuridine—Lethargy—Methotrexate—bone cancer	0.000657	0.0069	CcSEcCtD
Floxuridine—Ill-defined disorder—Cisplatin—bone cancer	0.000656	0.00688	CcSEcCtD
Floxuridine—Anaemia—Cisplatin—bone cancer	0.000653	0.00686	CcSEcCtD
Floxuridine—Thrombophlebitis—Doxorubicin—bone cancer	0.000644	0.00676	CcSEcCtD
Floxuridine—Malaise—Cisplatin—bone cancer	0.000637	0.00669	CcSEcCtD
Floxuridine—Photosensitivity—Doxorubicin—bone cancer	0.000635	0.00666	CcSEcCtD
Floxuridine—Leukopenia—Cisplatin—bone cancer	0.000633	0.00664	CcSEcCtD
Floxuridine—TYMS—Metabolism—NDUFA12—bone cancer	0.000622	0.00285	CbGpPWpGaD
Floxuridine—Lethargy—Epirubicin—bone cancer	0.000615	0.00645	CcSEcCtD
Floxuridine—Discomfort—Cisplatin—bone cancer	0.000594	0.00624	CcSEcCtD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.000592	0.00271	CbGpPWpGaD
Floxuridine—Anaphylactic shock—Cisplatin—bone cancer	0.000577	0.00605	CcSEcCtD
Floxuridine—Infection—Cisplatin—bone cancer	0.000573	0.00601	CcSEcCtD
Floxuridine—Lethargy—Doxorubicin—bone cancer	0.000569	0.00597	CcSEcCtD
Floxuridine—TYMS—Circadian rythm related genes—CDK4—bone cancer	0.000568	0.0026	CbGpPWpGaD
Floxuridine—Nervous system disorder—Cisplatin—bone cancer	0.000566	0.00594	CcSEcCtD
Floxuridine—Thrombocytopenia—Cisplatin—bone cancer	0.000565	0.00593	CcSEcCtD
Floxuridine—Dry skin—Epirubicin—bone cancer	0.000552	0.0058	CcSEcCtD
Floxuridine—Anorexia—Cisplatin—bone cancer	0.00055	0.00577	CcSEcCtD
Floxuridine—TYMS—Cell Cycle, Mitotic—DHFR—bone cancer	0.000546	0.0025	CbGpPWpGaD
Floxuridine—Gastritis—Epirubicin—bone cancer	0.000533	0.0056	CcSEcCtD
Floxuridine—Pancytopenia—Methotrexate—bone cancer	0.000529	0.00555	CcSEcCtD
Floxuridine—TYMS—Metabolism—NT5C3A—bone cancer	0.000516	0.00236	CbGpPWpGaD
Floxuridine—Dry skin—Doxorubicin—bone cancer	0.000511	0.00536	CcSEcCtD
Floxuridine—Photosensitivity reaction—Methotrexate—bone cancer	0.000508	0.00533	CcSEcCtD
Floxuridine—Angina pectoris—Epirubicin—bone cancer	0.000507	0.00532	CcSEcCtD
Floxuridine—Decreased appetite—Cisplatin—bone cancer	0.000501	0.00526	CcSEcCtD
Floxuridine—Pancytopenia—Epirubicin—bone cancer	0.000495	0.00519	CcSEcCtD
Floxuridine—Gastritis—Doxorubicin—bone cancer	0.000493	0.00518	CcSEcCtD
Floxuridine—TYMS—Cell Cycle—DHFR—bone cancer	0.000488	0.00223	CbGpPWpGaD
Floxuridine—Stomatitis—Methotrexate—bone cancer	0.000484	0.00508	CcSEcCtD
Floxuridine—Photosensitivity reaction—Epirubicin—bone cancer	0.000475	0.00499	CcSEcCtD
Floxuridine—Feeling abnormal—Cisplatin—bone cancer	0.000475	0.00499	CcSEcCtD
Floxuridine—TYMS—Retinoblastoma (RB) in Cancer—TP53—bone cancer	0.000472	0.00216	CbGpPWpGaD
Floxuridine—Angina pectoris—Doxorubicin—bone cancer	0.000469	0.00493	CcSEcCtD
Floxuridine—Epistaxis—Methotrexate—bone cancer	0.000468	0.00491	CcSEcCtD
Floxuridine—Agranulocytosis—Methotrexate—bone cancer	0.000463	0.00486	CcSEcCtD
Floxuridine—Pancytopenia—Doxorubicin—bone cancer	0.000458	0.0048	CcSEcCtD
Floxuridine—Body temperature increased—Cisplatin—bone cancer	0.000456	0.00479	CcSEcCtD
Floxuridine—Stomatitis—Epirubicin—bone cancer	0.000453	0.00475	CcSEcCtD
Floxuridine—Haemoglobin—Methotrexate—bone cancer	0.000448	0.0047	CcSEcCtD
Floxuridine—Haemorrhage—Methotrexate—bone cancer	0.000445	0.00468	CcSEcCtD
Floxuridine—Pharyngitis—Methotrexate—bone cancer	0.000442	0.00464	CcSEcCtD
Floxuridine—TYMP—Metabolism—ENO2—bone cancer	0.000442	0.00202	CbGpPWpGaD
Floxuridine—Photosensitivity reaction—Doxorubicin—bone cancer	0.00044	0.00462	CcSEcCtD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	0.000439	0.00201	CbGpPWpGaD
Floxuridine—Epistaxis—Epirubicin—bone cancer	0.000438	0.0046	CcSEcCtD
Floxuridine—Agranulocytosis—Epirubicin—bone cancer	0.000433	0.00455	CcSEcCtD
Floxuridine—Hypersensitivity—Cisplatin—bone cancer	0.000425	0.00446	CcSEcCtD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	0.000423	0.00194	CbGpPWpGaD
Floxuridine—Haemoglobin—Epirubicin—bone cancer	0.000419	0.0044	CcSEcCtD
Floxuridine—Stomatitis—Doxorubicin—bone cancer	0.000419	0.0044	CcSEcCtD
Floxuridine—Haemorrhage—Epirubicin—bone cancer	0.000417	0.00438	CcSEcCtD
Floxuridine—Asthenia—Cisplatin—bone cancer	0.000414	0.00434	CcSEcCtD
Floxuridine—Pharyngitis—Epirubicin—bone cancer	0.000414	0.00434	CcSEcCtD
Floxuridine—TYMP—Metabolism—DHFR—bone cancer	0.00041	0.00187	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle—CHEK2—bone cancer	0.000408	0.00186	CbGpPWpGaD
Floxuridine—Epistaxis—Doxorubicin—bone cancer	0.000405	0.00425	CcSEcCtD
Floxuridine—Agranulocytosis—Doxorubicin—bone cancer	0.000401	0.00421	CcSEcCtD
Floxuridine—Diarrhoea—Cisplatin—bone cancer	0.000395	0.00414	CcSEcCtD
Floxuridine—Alopecia—Methotrexate—bone cancer	0.000394	0.00413	CcSEcCtD
Floxuridine—Erythema—Methotrexate—bone cancer	0.000388	0.00407	CcSEcCtD
Floxuridine—Haemoglobin—Doxorubicin—bone cancer	0.000388	0.00407	CcSEcCtD
Floxuridine—Haemorrhage—Doxorubicin—bone cancer	0.000386	0.00405	CcSEcCtD
Floxuridine—TYMP—Metabolism—GNA11—bone cancer	0.000383	0.00175	CbGpPWpGaD
Floxuridine—Pharyngitis—Doxorubicin—bone cancer	0.000383	0.00402	CcSEcCtD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	0.000382	0.00174	CbGpPWpGaD
Floxuridine—Alopecia—Epirubicin—bone cancer	0.000368	0.00387	CcSEcCtD
Floxuridine—Vomiting—Cisplatin—bone cancer	0.000367	0.00385	CcSEcCtD
Floxuridine—TYMS—Circadian rythm related genes—JUN—bone cancer	0.000366	0.00168	CbGpPWpGaD
Floxuridine—Rash—Cisplatin—bone cancer	0.000364	0.00382	CcSEcCtD
Floxuridine—Dermatitis—Cisplatin—bone cancer	0.000363	0.00381	CcSEcCtD
Floxuridine—Erythema—Epirubicin—bone cancer	0.000363	0.00381	CcSEcCtD
Floxuridine—Ill-defined disorder—Methotrexate—bone cancer	0.00036	0.00378	CcSEcCtD
Floxuridine—Anaemia—Methotrexate—bone cancer	0.000358	0.00376	CcSEcCtD
Floxuridine—Malaise—Methotrexate—bone cancer	0.00035	0.00367	CcSEcCtD
Floxuridine—Muscle spasms—Epirubicin—bone cancer	0.000349	0.00366	CcSEcCtD
Floxuridine—TYMP—Metabolism—CYP3A4—bone cancer	0.000347	0.00159	CbGpPWpGaD
Floxuridine—Leukopenia—Methotrexate—bone cancer	0.000347	0.00364	CcSEcCtD
Floxuridine—TYMS—Cell Cycle—BRCA2—bone cancer	0.000346	0.00158	CbGpPWpGaD
Floxuridine—Nausea—Cisplatin—bone cancer	0.000343	0.0036	CcSEcCtD
Floxuridine—Alopecia—Doxorubicin—bone cancer	0.000341	0.00358	CcSEcCtD
Floxuridine—Ill-defined disorder—Epirubicin—bone cancer	0.000337	0.00353	CcSEcCtD
Floxuridine—Erythema—Doxorubicin—bone cancer	0.000336	0.00352	CcSEcCtD
Floxuridine—Anaemia—Epirubicin—bone cancer	0.000335	0.00352	CcSEcCtD
Floxuridine—Malaise—Epirubicin—bone cancer	0.000327	0.00343	CcSEcCtD
Floxuridine—Discomfort—Methotrexate—bone cancer	0.000326	0.00342	CcSEcCtD
Floxuridine—Leukopenia—Epirubicin—bone cancer	0.000325	0.00341	CcSEcCtD
Floxuridine—Muscle spasms—Doxorubicin—bone cancer	0.000323	0.00339	CcSEcCtD
Floxuridine—Confusional state—Methotrexate—bone cancer	0.000319	0.00335	CcSEcCtD
Floxuridine—Anaphylactic shock—Methotrexate—bone cancer	0.000316	0.00332	CcSEcCtD
Floxuridine—Infection—Methotrexate—bone cancer	0.000314	0.0033	CcSEcCtD
Floxuridine—Ill-defined disorder—Doxorubicin—bone cancer	0.000312	0.00327	CcSEcCtD
Floxuridine—Nervous system disorder—Methotrexate—bone cancer	0.00031	0.00326	CcSEcCtD
Floxuridine—Anaemia—Doxorubicin—bone cancer	0.00031	0.00326	CcSEcCtD
Floxuridine—Thrombocytopenia—Methotrexate—bone cancer	0.00031	0.00325	CcSEcCtD
Floxuridine—Discomfort—Epirubicin—bone cancer	0.000305	0.0032	CcSEcCtD
Floxuridine—Malaise—Doxorubicin—bone cancer	0.000303	0.00318	CcSEcCtD
Floxuridine—Anorexia—Methotrexate—bone cancer	0.000302	0.00317	CcSEcCtD
Floxuridine—Leukopenia—Doxorubicin—bone cancer	0.000301	0.00315	CcSEcCtD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	0.0003	0.00137	CbGpPWpGaD
Floxuridine—Confusional state—Epirubicin—bone cancer	0.000299	0.00313	CcSEcCtD
Floxuridine—TYMP—Metabolism—GSTP1—bone cancer	0.000297	0.00136	CbGpPWpGaD
Floxuridine—Anaphylactic shock—Epirubicin—bone cancer	0.000296	0.00311	CcSEcCtD
Floxuridine—Infection—Epirubicin—bone cancer	0.000294	0.00309	CcSEcCtD
Floxuridine—Nervous system disorder—Epirubicin—bone cancer	0.00029	0.00305	CcSEcCtD
Floxuridine—Thrombocytopenia—Epirubicin—bone cancer	0.00029	0.00304	CcSEcCtD
Floxuridine—TYMS—Cell Cycle, Mitotic—CDK4—bone cancer	0.000287	0.00131	CbGpPWpGaD
Floxuridine—Discomfort—Doxorubicin—bone cancer	0.000282	0.00296	CcSEcCtD
Floxuridine—Anorexia—Epirubicin—bone cancer	0.000282	0.00296	CcSEcCtD
Floxuridine—Confusional state—Doxorubicin—bone cancer	0.000276	0.0029	CcSEcCtD
Floxuridine—Decreased appetite—Methotrexate—bone cancer	0.000275	0.00289	CcSEcCtD
Floxuridine—Anaphylactic shock—Doxorubicin—bone cancer	0.000274	0.00288	CcSEcCtD
Floxuridine—Infection—Doxorubicin—bone cancer	0.000272	0.00286	CcSEcCtD
Floxuridine—Nervous system disorder—Doxorubicin—bone cancer	0.000269	0.00282	CcSEcCtD
Floxuridine—Thrombocytopenia—Doxorubicin—bone cancer	0.000268	0.00282	CcSEcCtD
Floxuridine—Anorexia—Doxorubicin—bone cancer	0.000261	0.00274	CcSEcCtD
Floxuridine—Feeling abnormal—Methotrexate—bone cancer	0.000261	0.00274	CcSEcCtD
Floxuridine—Gastrointestinal pain—Methotrexate—bone cancer	0.000259	0.00272	CcSEcCtD
Floxuridine—Decreased appetite—Epirubicin—bone cancer	0.000257	0.0027	CcSEcCtD
Floxuridine—TYMS—Cell Cycle—CDK4—bone cancer	0.000256	0.00117	CbGpPWpGaD
Floxuridine—TYMS—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	0.000252	0.00115	CbGpPWpGaD
Floxuridine—Abdominal pain—Methotrexate—bone cancer	0.00025	0.00263	CcSEcCtD
Floxuridine—Body temperature increased—Methotrexate—bone cancer	0.00025	0.00263	CcSEcCtD
Floxuridine—TYMS—Cell Cycle, Mitotic—RB1—bone cancer	0.000249	0.00114	CbGpPWpGaD
Floxuridine—Feeling abnormal—Epirubicin—bone cancer	0.000244	0.00256	CcSEcCtD
Floxuridine—Gastrointestinal pain—Epirubicin—bone cancer	0.000242	0.00254	CcSEcCtD
Floxuridine—TYMS—Circadian rythm related genes—TP53—bone cancer	0.000242	0.00111	CbGpPWpGaD
Floxuridine—Decreased appetite—Doxorubicin—bone cancer	0.000238	0.0025	CcSEcCtD
Floxuridine—Abdominal pain—Epirubicin—bone cancer	0.000234	0.00246	CcSEcCtD
Floxuridine—Body temperature increased—Epirubicin—bone cancer	0.000234	0.00246	CcSEcCtD
Floxuridine—Hypersensitivity—Methotrexate—bone cancer	0.000233	0.00245	CcSEcCtD
Floxuridine—Asthenia—Methotrexate—bone cancer	0.000227	0.00238	CcSEcCtD
Floxuridine—TYMS—Metabolism—ENO2—bone cancer	0.000226	0.00103	CbGpPWpGaD
Floxuridine—Feeling abnormal—Doxorubicin—bone cancer	0.000226	0.00237	CcSEcCtD
Floxuridine—Gastrointestinal pain—Doxorubicin—bone cancer	0.000224	0.00235	CcSEcCtD
Floxuridine—TYMS—Cell Cycle—RB1—bone cancer	0.000223	0.00102	CbGpPWpGaD
Floxuridine—Hypersensitivity—Epirubicin—bone cancer	0.000218	0.00229	CcSEcCtD
Floxuridine—Abdominal pain—Doxorubicin—bone cancer	0.000217	0.00227	CcSEcCtD
Floxuridine—Body temperature increased—Doxorubicin—bone cancer	0.000217	0.00227	CcSEcCtD
Floxuridine—Diarrhoea—Methotrexate—bone cancer	0.000217	0.00227	CcSEcCtD
Floxuridine—Asthenia—Epirubicin—bone cancer	0.000212	0.00223	CcSEcCtD
Floxuridine—TYMS—Metabolism—DHFR—bone cancer	0.00021	0.000959	CbGpPWpGaD
Floxuridine—Diarrhoea—Epirubicin—bone cancer	0.000203	0.00213	CcSEcCtD
Floxuridine—Hypersensitivity—Doxorubicin—bone cancer	0.000202	0.00212	CcSEcCtD
Floxuridine—Vomiting—Methotrexate—bone cancer	0.000201	0.00211	CcSEcCtD
Floxuridine—Rash—Methotrexate—bone cancer	0.0002	0.00209	CcSEcCtD
Floxuridine—Dermatitis—Methotrexate—bone cancer	0.000199	0.00209	CcSEcCtD
Floxuridine—Headache—Methotrexate—bone cancer	0.000198	0.00208	CcSEcCtD
Floxuridine—Asthenia—Doxorubicin—bone cancer	0.000197	0.00206	CcSEcCtD
Floxuridine—TYMS—Metabolism—GNA11—bone cancer	0.000196	0.000896	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle—MDM2—bone cancer	0.00019	0.000869	CbGpPWpGaD
Floxuridine—Vomiting—Epirubicin—bone cancer	0.000188	0.00198	CcSEcCtD
Floxuridine—Nausea—Methotrexate—bone cancer	0.000188	0.00197	CcSEcCtD
Floxuridine—Diarrhoea—Doxorubicin—bone cancer	0.000188	0.00197	CcSEcCtD
Floxuridine—Rash—Epirubicin—bone cancer	0.000187	0.00196	CcSEcCtD
Floxuridine—Dermatitis—Epirubicin—bone cancer	0.000187	0.00196	CcSEcCtD
Floxuridine—Headache—Epirubicin—bone cancer	0.000186	0.00195	CcSEcCtD
Floxuridine—TYMS—Metabolism—CYP3A4—bone cancer	0.000178	0.000812	CbGpPWpGaD
Floxuridine—Nausea—Epirubicin—bone cancer	0.000176	0.00185	CcSEcCtD
Floxuridine—Vomiting—Doxorubicin—bone cancer	0.000174	0.00183	CcSEcCtD
Floxuridine—Rash—Doxorubicin—bone cancer	0.000173	0.00181	CcSEcCtD
Floxuridine—Dermatitis—Doxorubicin—bone cancer	0.000173	0.00181	CcSEcCtD
Floxuridine—Headache—Doxorubicin—bone cancer	0.000172	0.0018	CcSEcCtD
Floxuridine—Nausea—Doxorubicin—bone cancer	0.000163	0.00171	CcSEcCtD
Floxuridine—TYMP—Metabolism—PTGS2—bone cancer	0.000154	0.000704	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—GSTP1—bone cancer	0.000152	0.000695	CbGpPWpGaD
Floxuridine—TYMS—Cell Cycle—TP53—bone cancer	0.000109	0.000499	CbGpPWpGaD
Floxuridine—TYMS—Metabolism—PTGS2—bone cancer	7.87e-05	0.00036	CbGpPWpGaD
